Építés alatt – nem éles oldal
Belépés
Résztvevőt keres itt: Egyesült ÁllamokFázis nélkül

Olfactory Training in Mild Cognitive Impairment

A legfontosabb adatok

Ki végzi
Jeffrey Motter
Hol
New York (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Toboroz
Résztvevők
30 fő, tervezett
Kezdés
2025. aug. 7.
Várható befejezés
2028. márc. 31.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Olfactory Memory Training
  • Visual Memory Training
A regiszteradat frissítve
2026. szeptember 4.

Ki vehet részt

MI-összefoglaló

A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.

The trial is looking for people aged 55-89 with mild cognitive impairment, an early stage of memory loss. Participants do either smell memory training or visual memory training for 3 months.

Életkor
55 to 89 years
Nem
All sexes
A betegség stádiuma
Mild cognitive impairment, early or late, shown by a low score on a memory test (Logical Memory II, WMS-III). Montreal Cognitive Assessment score >=17. Memory or other thinking complaints. No dementia.
Korábbi kezelés
People cannot take part in another treatment trial of a drug, device or procedure for thinking at the same time.

A részvétel fő kizáró okai

  • Dementia of any type, or brain conditions such as Parkinson's disease, stroke, epilepsy or multiple sclerosis
  • Schizophrenia, bipolar disorder, alcohol or substance use disorder, or unstable or untreated major depression
  • Severe or recent asthma, smoking more than 1 pack a day, a current cold or other upper airway infection, or being born without a sense of smell
  • Pregnancy, breastfeeding, or nose medicines other than nasal steroids for rhinitis
  • Severe nose symptoms, allergy to the test odors, or a severe, unstable illness

A regiszter feltételei, szó szerint

Mind a 16 feltétel megnézéseKevesebb

Ki vehet részt

  • Age 55-89 at the time of informed consent
  • Montreal Cognitive Assessment score >=17
  • Subjective cognitive complaints, i.e., memory or other cognitive complaints, e.g., naming/language
  • Meets criteria for cognitive impairment (CI), including either early mild cognitive impairment (eMCI) or late mild cognitive impairment (lMCI), defined as memory function documented by scoring below the education adjusted cutoff on the Logical Memory II subscale (Story A, Delayed Paragraph Recall) from the Wechsler Memory Scale (WMS) - III (the maximum score is 25). The criteria for MCI (includes eMCI and lMCI) are as follows: eMCI is defined by a WMS-III Logical memory delayed recall score of 3-6 with 0-7 years of education, score of 5-9 with 8-15 years of education, and score of 9-11 with 16 or more years of education. lMCI is defined by a WMS-III Logical Memory delayed recall score ≤ 2 with 0-7 years of education, score ≤ 4 with 8-15 years of education, and score ≤ 8 with ≥ 16 years of education
  • An informant (relative, friend, other caregiver) who contacts the participant at least weekly is required to provide information about the participant's functioning. If the informant drops out, an alternate informant can be designated by the participant

Ki nem vehet részt

  • Participation concurrently in another therapeutic clinical trial of a cognitive enhancing drug or device or procedure
  • Diagnosis of dementia of any type
  • Neurological disorders including Parkinson's disease, Huntington's disease, multiple sclerosis, stroke, epilepsy, traumatic brain injury (moderate to severe, with greater than 30 min loss of consciousness), and other neurologic disorders with focal signs (e.g., amyotrophic lateral sclerosis)
  • Current clinical diagnosis of schizophrenia, schizoaffective disorder, bipolar disorder, alcohol use disorder, or substance use disorder (Diagnostic and Statistical Manual of Mental Disorders (DSM)-5-Text Revision criteria)
  • Acute, severe unstable medical illness in the judgment of the clinician. For cancer, acutely ill participants (including those with metastases) are excluded, but history of successfully treated cancer does not result in exclusion
  • Current upper respiratory infection (participant rescheduled as soon as this improves), current smoker >1 pack daily (past smoking has been shown not to affect odor identification scores), self-reported congenital anosmia
  • Severe vision, hearing, or tactile impairment that would prevent the participant from performing the cognitive tests accurately. This will be a clinical determination
  • History of severe or recent asthma (defined as use of an inhaler for asthma, use of other asthma medication, or occurrence of an asthma attack within the last ten years), known special sensitivities to volatile chemicals, anyone who believes she is pregnant or is nursing a baby, and anyone who is on nasally administered medications other than people on nasal steroids to control rhinitis, allergic and otherwise
  • Allergies to any odors used in the olfactory testing or olfactory memory training
  • Current unstable or untreated major depression, Geriatric Depression Scale (Short Form) score >= 6, or active suicidality based on a suicide scale (Columbia-Suicide Severity Rating Scale Screen version: positive answer to question 1 or 2 followed by item 6 positive answer leads to exclusion. Negative answer to questions 1 and 2: interview ends and the participant is not excluded for active suicidality)
  • Sino-nasal Outcome Test-22 nasal domain score >21, or individual score = 5, representing severe nasal symptoms that interfere with olfaction

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 55 és 89 év között vagy?

Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.

  • New York State Psychiatric InstituteNew York, Egyesült ÁllamokContact: Jeffrey Motter, PhDRésztvevőt keres

A vizsgálatról

Mit akar kideríteni a vizsgálat

Sense of smell tends to decline in individuals with early Alzheimer's disease, typically earlier than when other senses and thinking abilities begin to decline. Memory for new odors is particularly diminished in these individuals. Existing treatments for AD do not improve these symptoms. A targeted treatment for improving sense of smell, called 'Olfactory Training', has been used to improve sense of smell in people with various forms of smell loss, though it is not known whether it can improve smell abilities and thinking abilities in patients who are at high risk of developing Alzheimer's disease. The investigators will conduct a randomized clinical trial with patients who have mild cognitive impairment (MCI). This is an early phase of memory loss that is worse than normal aging and may precede Alzheimer's disease. Patients will be randomized to either olfactory memory training or visual memory training for 3 months, with a final follow-up visit at 6 months. This study will attempt to determine if olfactory training is a useful for improving smell abilities, thinking abilities, and everyday functioning by examining change in these outcomes over time.

A vizsgálat 2 csoportja

  • Olfactory Memory TrainingMár használt kezelés, összehasonlításként
  • Visual Memory TrainingMár használt kezelés, összehasonlításként

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 15.
Kérdések a feltételekről
Forrás: NCT06825403: ki vehet részt
A regiszteradat frissítve
2026. szeptember 4.